VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:VX1 - US92532F1003 - Common Stock
373.85 EUR
-2.6 (-0.69%)
Taking everything into account, VX1 scores 7 out of 10 in our fundamental rating. VX1 was compared to 78 industry peers in the Biotechnology industry. VX1 gets an excellent profitability rating and is at the same time showing great financial health properties. VX1 has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make VX1 a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
VX1 had positive earnings in the past year.
In the past year VX1 had a positive cash flow from operations.
VX1 had positive earnings in 4 of the past 5 years.
Of the past 5 years VX1 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 14.78%, VX1 belongs to the top of the industry, outperforming 89.74% of the companies in the same industry.
VX1 has a Return On Equity of 21.22%. This is amongst the best in the industry. VX1 outperforms 92.31% of its industry peers.
With an excellent Return On Invested Capital value of 15.66%, VX1 belongs to the best of the industry, outperforming 93.59% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for VX1 is significantly above the industry average of 12.34%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROIC | 15.67% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
1.3 Margins
The Profit Margin of VX1 (31.35%) is better than 89.74% of its industry peers.
VX1 has a Operating Margin of 38.70%. This is amongst the best in the industry. VX1 outperforms 93.59% of its industry peers.
In the last couple of years the Operating Margin of VX1 has grown nicely.
The Gross Margin of VX1 (86.28%) is better than 78.21% of its industry peers.
In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
VX1 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for VX1 has been reduced compared to 1 year ago.
The number of shares outstanding for VX1 has been reduced compared to 5 years ago.
Compared to 1 year ago, VX1 has an improved debt to assets ratio.
2.2 Solvency
There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.8
WACC8.7%
2.3 Liquidity
VX1 has a Current Ratio of 2.36. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1 has a Current ratio of 2.36. This is comparable to the rest of the industry: VX1 outperforms 58.97% of its industry peers.
VX1 has a Quick Ratio of 2.00. This is a normal value and indicates that VX1 is financially healthy and should not expect problems in meeting its short term obligations.
VX1 has a Quick ratio (2.00) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 3303.92%, which is quite impressive.
VX1 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -44.14% yearly.
The Revenue has grown by 10.33% in the past year. This is quite good.
Measured over the past years, VX1 shows a very strong growth in Revenue. The Revenue has been growing by 21.50% on average per year.
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
3.2 Future
The Earnings Per Share is expected to grow by 149.22% on average over the next years. This is a very strong growth
VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.58% yearly.
EPS Next Y6237.82%
EPS Next 2Y744.13%
EPS Next 3Y327.84%
EPS Next 5Y149.22%
Revenue Next Year10.08%
Revenue Next 2Y9.82%
Revenue Next 3Y9.46%
Revenue Next 5Y9.58%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 24.86 indicates a rather expensive valuation of VX1.
VX1's Price/Earnings ratio is rather cheap when compared to the industry. VX1 is cheaper than 84.62% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.65. VX1 is around the same levels.
With a Price/Forward Earnings ratio of 20.89, VX1 is valued on the expensive side.
VX1's Price/Forward Earnings ratio is rather cheap when compared to the industry. VX1 is cheaper than 89.74% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of VX1 to the average of the S&P500 Index (34.45), we can say VX1 is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.86 | ||
| Fwd PE | 20.89 |
4.2 Price Multiples
78.21% of the companies in the same industry are more expensive than VX1, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VX1 indicates a rather cheap valuation: VX1 is cheaper than 84.62% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.16 | ||
| EV/EBITDA | 22.03 |
4.3 Compensation for Growth
VX1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of VX1 may justify a higher PE ratio.
VX1's earnings are expected to grow with 327.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y744.13%
EPS Next 3Y327.84%
5. Dividend
5.1 Amount
No dividends for VX1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:VX1 (11/24/2025, 7:00:00 PM)
373.85
-2.6 (-0.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.11%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap95.85B
Revenue(TTM)11.72B
Net Income(TTM)3.68B
Analysts76.41
Price Target430.81 (15.24%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)2.97%
PT rev (3m)1.36%
EPS NQ rev (1m)3.56%
EPS NQ rev (3m)1.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.3%
Revenue NQ rev (1m)-1.07%
Revenue NQ rev (3m)-1.07%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.86 | ||
| Fwd PE | 20.89 | ||
| P/S | 9.44 | ||
| P/FCF | 33.16 | ||
| P/OCF | 29.76 | ||
| P/B | 6.39 | ||
| P/tB | 7 | ||
| EV/EBITDA | 22.03 |
EPS(TTM)15.04
EY4.02%
EPS(NY)17.9
Fwd EY4.79%
FCF(TTM)11.28
FCFY3.02%
OCF(TTM)12.56
OCFY3.36%
SpS39.61
BVpS58.51
TBVpS53.39
PEG (NY)0
PEG (5Y)N/A
Graham Number140.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROCE | 22.25% | ||
| ROIC | 15.67% | ||
| ROICexc | 22.65% | ||
| ROICexgc | 25.38% | ||
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% | ||
| FCFM | 28.47% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 189.83% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 374.91 | ||
| Cash Conversion | 78.49% | ||
| Profit Quality | 90.81% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 | ||
| Altman-Z | N/A |
F-Score7
WACC8.7%
ROIC/WACC1.8
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
EPS Next Y6237.82%
EPS Next 2Y744.13%
EPS Next 3Y327.84%
EPS Next 5Y149.22%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
Revenue Next Year10.08%
Revenue Next 2Y9.82%
Revenue Next 3Y9.46%
Revenue Next 5Y9.58%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year820.09%
EBIT Next 3Y129.43%
EBIT Next 5Y68.42%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.
What is the valuation status of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Undervalued.
What is the profitability of VX1 stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (VX1.DE) is 24.86 and the Price/Book (PB) ratio is 6.39.
What is the financial health of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.